Delårsrapport 1 januari – 30 september 2018
November 14, 2018 02:30 ET | AroCell AB
     Väsentliga händelser under perioden 1 januari till 30 september AroCell ingick ett icke exklusivt licensavtal med Roche Diagnostics, ett av världens största diagnostikbolag med fokus på...
A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method
October 09, 2018 02:40 ET | AroCell AB
AroCell AB announces today that a second abstract has been accepted by ISOBM (International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany...
Ytterligare ett abstract som visar värdet av AroCells provberedningssteg i samband med diagnostik har accepterats av ISOBM inför mötet i Hamburg
October 09, 2018 02:40 ET | AroCell AB
AroCell meddelar idag att ytterligare ett abstract har accepterats av ISOBM (International Society of Oncology and BioMarkers) för presentation som poster vid organisationens årliga konferens i...
A new study comparing TK 210™ ELISA from AroCell with other activity-based assays for the measurement of TK1 in serum shows high correlation between methods when samples from subjects with hematological malignancies are compared. The study
September 18, 2018 05:30 ET | AroCell AB
An abstract entitled “A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance”, by Staffan Eriksson et...
En ny studie som jämför TK 210™ ELISA med aktivitetsbaserade assays utvecklade att mäta TK1 i serum, visar en hög korrelation mellan metoderna när prover från personer med hematologiska maligniteter analyseras. Studien kommer att presentera
September 18, 2018 05:30 ET | AroCell AB
Ett abstract med titeln " A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance", författat av Staffan...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
August 24, 2018 07:50 ET | AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...